AMPH (Amphastar Pharmaceuticals) Cyclically Adjusted FCF per Share: $1.36 (As of Mar. 2026)


AMPH Amphastar Pharmaceuticals Inc AMPH
83 GF Score
Price $20.10
GF Value $48.78
Valuation Significantly Undervalued
! 5 Warning Signs
View Full Analysis

What is Amphastar Pharmaceuticals Cyclically Adjusted FCF per Share?

Amphastar Pharmaceuticals AMPH -0.40% 83 Cyclically Adjusted FCF per Share is $1.36 as of Mar. 2026. GuruFocus rates AMPH with a GF Score™ of 83/100 and a GF Value™ of $48.78 (Significantly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Amphastar Pharmaceuticals's adjusted free cash flow per share for the three months ended in Mar. 2026 was $0.825. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $1.36 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Amphastar Pharmaceuticals's average Cyclically Adjusted FCF Growth Rate was 28.30% per year. During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was 31.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Amphastar Pharmaceuticals was 31.70% per year. The lowest was 31.70% per year. And the median was 31.70% per year.

As of today (2026-07-01), Amphastar Pharmaceuticals's current stock price is $20.10. Amphastar Pharmaceuticals's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2026 was $1.36. Amphastar Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is 14.78.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Amphastar Pharmaceuticals was 118.51. The lowest was 12.40. And the median was 50.18.


Amphastar Pharmaceuticals  (NAS:AMPH) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.

Amphastar Pharmaceuticals's Cyclically Adjusted Price-to-FCF of today is calculated as

Cyclically Adjusted Price-to-FCF=Share Price/Cyclically Adjusted FCF per Share
=20.10/1.36
=14.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted Price-to-FCF of Amphastar Pharmaceuticals was 118.51. The lowest was 12.40. And the median was 50.18.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Amphastar Pharmaceuticals Cyclically Adjusted FCF per Share Related Terms


Amphastar Pharmaceuticals Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Amphastar Pharmaceuticals's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amphastar Pharmaceuticals Cyclically Adjusted FCF per Share Chart

Amphastar Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.56 0.64 0.99 1.28

Amphastar Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.06 1.12 1.23 1.28 1.36

AMPH vs ETON, PCRX, BIOA: Cyclically Adjusted FCF per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Amphastar Pharmaceuticals's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amphastar Pharmaceuticals Cyclically Adjusted Price-to-FCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amphastar Pharmaceuticals's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Amphastar Pharmaceuticals's Cyclically Adjusted Price-to-FCF falls into.


AMPH
83GF Score
Amphastar Pharmaceuticals Inc AMPH
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Amphastar Pharmaceuticals Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Amphastar Pharmaceuticals's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.825/330.2130*330.2130
=0.825

Current CPI (Mar. 2026) = 330.2130.

Amphastar Pharmaceuticals Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201606 0.085 241.018 0.116
201609 -0.113 241.428 -0.155
201612 0.170 241.432 0.233
201703 0.315 243.801 0.427
201706 -0.036 244.955 -0.049
201709 -0.185 246.819 -0.248
201712 -0.007 246.524 -0.009
201803 -0.086 249.554 -0.114
201806 -0.166 251.989 -0.218
201809 0.065 252.439 0.085
201812 -0.001 251.233 -0.001
201903 -0.367 254.202 -0.477
201906 0.845 256.143 1.089
201909 -0.413 256.759 -0.531
201912 -0.056 256.974 -0.072
202003 -0.135 258.115 -0.173
202006 0.411 257.797 0.526
202009 0.064 260.280 0.081
202012 0.152 260.474 0.193
202103 0.307 264.877 0.383
202106 0.533 271.696 0.648
202109 -0.093 274.310 -0.112
202112 0.670 278.802 0.794
202203 0.859 287.504 0.987
202206 -0.059 296.311 -0.066
202209 0.279 296.808 0.310
202212 0.172 296.797 0.191
202303 0.595 301.836 0.651
202306 0.864 305.109 0.935
202309 1.004 307.789 1.077
202312 0.272 306.746 0.293
202403 0.877 312.332 0.927
202406 1.212 314.175 1.274
202409 0.890 315.301 0.932
202412 0.324 315.605 0.339
202503 0.489 319.799 0.505
202506 0.473 322.561 0.484
202509 0.991 324.800 1.008
202512 0.521 324.054 0.531
202603 0.825 330.213 0.825

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of $1.36 mean?
Amphastar Pharmaceuticals (AMPH) has a Cyclically Adjusted FCF per Share of $1.36 as of Mar. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Amphastar Pharmaceuticals and its competitors.
Is Amphastar Pharmaceuticals' Cyclically Adjusted FCF per Share too high?
Amphastar Pharmaceuticals' current Cyclically Adjusted FCF per Share is $1.36. Overall, Amphastar Pharmaceuticals has a GF Score™ of 83/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Amphastar Pharmaceuticals' Cyclically Adjusted FCF per Share compare to ETON and PCRX?
Amphastar Pharmaceuticals' Cyclically Adjusted FCF per Share of $1.36 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Drug Manufacturers company?
A good Cyclically Adjusted FCF per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Amphastar Pharmaceuticals and its competitors. Amphastar Pharmaceuticals's current Cyclically Adjusted FCF per Share is $1.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Amphastar Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Amphastar Pharmaceuticals (AMPH) is currently considered Significantly Undervalued. The stock's GF Value™ is $48.78, compared to a current price of $20.10 — trading 58.8% below its estimated fair value. The current Cyclically Adjusted FCF per Share is $1.36. Amphastar Pharmaceuticals' overall GF Score™ is 83/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Amphastar Pharmaceuticals (AMPH), the current Cyclically Adjusted FCF per Share is $1.36 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Amphastar Pharmaceuticals (AMPH) Overvalued in 2026?

Based on GuruFocus' analysis, Amphastar Pharmaceuticals stock appears to be undervalued. The current stock price of $20.10 is trading 58.8% below its estimated GF Value™ of $48.78. GuruFocus considers Amphastar Pharmaceuticals to be Significantly Undervalued.

Key valuation signals for AMPH:

  • Cyclically Adjusted FCF per Share: $1.36
  • GF Value™: $48.78 vs. price of $20.10 (58.8% below fair value)
  • GF Score™: 83/100 with 5 warning signs

No single metric tells the full story. See the AMPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Amphastar Pharmaceuticals Business Description

Other Exchanges 29A:Germany
Address 11570 6th Street, Rancho Cucamonga, CA, USA, 91730
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient (or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment: pharmaceutical products. Geographically, the business presence of the firm is seen in the United States, China, and France, of which the U.S. accounts for the majority of the revenue.
83GF Score

Get the complete analysis for AMPH

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$20.10
Price
$48.78
GF Value